Mirvetuximab soravtansine improved overall survival, progression-free survival, second progression-free survival, and other outcomes.
The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...
Compass Therapeutics (NASDAQ:CMPX) stock gains as its oncology drug tovecimig hits main goal in a Phase 2/3 trial for biliary ...
Clinical Trials Arena on MSN1d
Corcept’s Phase III trial of ovarian cancer therapy shows PFS improvementThe trial outcomes are said to support a new drug application in the US and a European marketing authorisation application.
Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science ...
Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to ...
MyChesCo on MSN2d
AstraZeneca Showcases TAGRISSO’s Potential in EGFR-Mutated Lung Cancer at ELCC 2025AstraZeneca presented new data on TAGRISSO® (osimertinib) at the European Lung Cancer Congress (ELCC) 2025, reinforcing its ...
OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to ...
The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...
The Apple Watch offers plenty of health features, but Apple is apparently stepping things up with an AI doctor of sorts.
Patients with metastatic NSCLC may benefit from continuing on pembrolizumab-based treatment after progressing on that ...
Final phase 2a results showed that CAN-2409 led to a median overall survival of 24.5 months in immune checkpoint ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback